The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors
Benoı̂t Rousseau(Memorial Sloan Kettering Cancer Center), Michael B. Foote(Memorial Sloan Kettering Cancer Center), Steven B. Maron(Memorial Sloan Kettering Cancer Center), Bill H. Diplas(Memorial Sloan Kettering Cancer Center), Steve Lu(Johns Hopkins University), Guillem Argilés(Memorial Sloan Kettering Cancer Center), Andrea Cercek(Memorial Sloan Kettering Cancer Center), Luis A. Díaz(Memorial Sloan Kettering Cancer Center)
Cited by 210Open Access
Abstract
Immune Checkpoint Inhibitors and Tumor Mutational Burden The FDA has approved immune checkpoint inhibitors for solid tumors of any histologic origin with more than 10 mutations per megabase of DNA....
Related Papers
No related papers found
Powered by citation graph analysis